Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT IT: SARS-CoVSTs for COVID-19
NCT04401410Phase 1Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Partially HLA-matched SARS-CoVSTs in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Baylor College of Medicine. Primary endpoints: Rate of Dose Limiting Toxicities at 14 days and Rate of Clinical Response at 7 days. Started Nov 2020; status: terminated.
02
Drugs
Partially HLA-matched SARS-CoVSTs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04401410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401410.